Drug
Mirikizumab clinical trials
Also written LY3074828 and Omvoh.
- studies test it
- 44
- open now
- 12
- in phase 3
- 13
- first study started
- 2013
Keep track of what changes. Save the mirikizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
44 studies that test it; most in 2018 (10)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 10 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 17
- Phase 2
- 4
- Phase 3
- 13
- Phase 4
- 10
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 36 · Other 8
Eli Lilly and Company (35) · University Hospital Schleswig-Holstein (2) · Showa Inan General Hospital (1) · Specialty Networks Research. (1) · Icahn School of Medicine at Mount Sinai (1) · Rubix LS (1) · Alimentiv Inc. (1) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (1)
Often tested with
Tested in the same studies.
LY900021 (2) · Vedolizumab (1)
Studies
Open first, then newest update. How each study uses mirikizumab is read from its arms, and is right about nine times in ten.
Testing it · 44
- A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)RecruitingPhase 3Eli Lilly and CompanyNCT04844606Written as Mirikizumab
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's DiseaseRecruitingPhase 3Eli Lilly and CompanyNCT05509777Written as Mirikizumab
- INSIGHT-IBD Pragmatic StudyEnrolling by invitationPhase 4Specialty Networks Research.NCT07686757Written as Mirikizumab
- A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved IndicationRecruitingPhase 4Eli Lilly and CompanyNCT07612267Written as Mirikizumab
- MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's DiseaseNot yet recruitingPhase 4Icahn School of Medicine at Mount SinaiNCT07782021Written as Mirikizumab
- Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CDRecruitingPhase 4Alimentiv Inc.NCT06997965Written as Mirikizumab
- Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed, Moderate-to-severe Crohn's DiseaseNot yet recruitingPhase 4University Hospital Schleswig-HolsteinNCT07659353Written as Mirikizumab
- Efficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's DiseaseRecruitingPhase 4Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesNCT07292012Written as Mirikizumab - IV
- A Study of Mirikizumab Solution (LY3074828) in Healthy ParticipantsRecruitingPhase 1Eli Lilly and CompanyNCT07446101Written as Mirikizumab
- Mirikizumab in the Treatment of Chronic Inflammatory Conditions of the PouchRecruitingPhase 4University of North Carolina, Chapel HillNCT06864403Written as Mirikizumab - Intravenous (IV)
- Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative ColitisRecruitingPhase 4University Hospital Schleswig-HolsteinNCT07235904Written as Mirikizumab
- Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative ColitisNot yet recruitingPhase 4Rubix LSNCT07059130Written as Mirikizumab
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's DiseaseActive, not recruitingPhase 3Eli Lilly and CompanyNCT04232553Written as Mirikizumab
- A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Eli Lilly and CompanyNCT05767021Written as Mirikizumab
- A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative ColitisCompletedPhase 3Eli Lilly and CompanyNCT05784246Written as Mirikizumab IV
- A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedPhase 3Eli Lilly and CompanyNCT03524092Written as Mirikizumab SC
- A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)Active, not recruitingPhase 3Eli Lilly and CompanyNCT03519945Written as Mirikizumab
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06475729Written as Citrate-Free Mirikizumab
- Association Between Effectiveness of Mirikizumab and UC Patients With High Neutrophilic Infiltration in Epithelium of the Colonic MucosaCompletedPhase 4Showa Inan General HospitalNCT06626165Written as Mirikizumab
- An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)CompletedPhase 3Eli Lilly and CompanyNCT03518086Written as Mirikizumab
See all 44 studies that test mirikizumab →
Given in every arm · 7 — mirikizumab is usual care beside what is tested
- A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's DiseaseRecruitingPhase 2Eli Lilly and CompanyNCT07483073Written as Mirikizumab - Intravenous (IV)
- LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:RecruitingPhase 2Eli Lilly and CompanyNCT07186101Written as Mirikizumab
- A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's DiseaseRecruitingPhase 2Eli Lilly and CompanyNCT07483099Written as Mirikizumab - Intravenous (IV)
- Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b StudyRecruitingPhase 3Eli Lilly and CompanyNCT06937086Written as Mirikizumab
- Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or OverweightRecruitingPhase 3Eli Lilly and CompanyNCT06937099Written as Mirikizumab
- A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative ColitisActive, not recruitingPhase 2Eli Lilly and CompanyNCT06598943Written as Mirikizumab
- A Study of Injections of LY3074828 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT03886948Written as LY3074828
Codes
What other systems call mirikizumab · ClinicalTrials.gg INT001359
- MeSH (NLM) C000708407mirikizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Z7HVY03PHPMIRIKIZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q55641096mirikizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170182MirikizumabOne source FDA
- DrugBank DB14910One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708407 | mirikizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Z7HVY03PHP | MIRIKIZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q55641096 | mirikizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170182 | Mirikizumab | One source FDA |
| DrugBank | DB14910 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.